This is a follow-up of a very successful series of (1) International Regulatory Workshops on Bioequivalence, Bioanalysis, Dissolution and Biosimilarity (BEW Series) and (2) International Symposium on Scientific and Regulatory Advances in Biological and Non-Biological Complex Drugs: A to Z in Bioequivalence (SRACD Series). With the progressing science and technologies, the pharmaceutical world has entered into advanced targeted drug therapies, delivery systems, and dosage forms and more generally into medicines with higher complexity including nanopharmaceuticals. The conference will address new trends in pharmaceutical, regulatory science of biological and non-biological complex drugs (NBCDs) and the challenges for their correct use. Keynote addresses will provide different perspectives on where we came from, where we are and where we are heading to. Topics will be addressed regarding the bioequivalence evaluation of complex drugs. The conference will update on regulatory harmonization attempts for the bioequivalence of complex drugs with an insight into drug dissolution/drug release, nano-medicines, biodegradable polymers and bioanalytics as a sensitive and specific state of the art assessment method today. Prominent representatives of pharmaceutical authorities are invited to contribute to the scientific programme, as well as prescribers and users of highly complex drug products and their follow-ons versions. The First Circular of the DDRS 2020 Conference is available at:
I would like to call your kind attention that the organisers offer best poster awards to three presenters which will be given at the closing ceremony of the Conference. Should you need assistance regarding the abstract submission or registration procedure, please, do not hesitate to contact the organisers at email@example.com .